Triumvira Immunologics, Inc.   Report issue

For profit Phase 2
Founded: Austin TX United States (2015)

Organization Overview

First Clinical Trial
2019
NCT03880279
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Triumvira Immunologics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

tac01-cd19 (1 trial)

tac01-her2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2